VRCA — Verrica Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1660334 ·
Last close
$4.37
Market Cap
$75.07M
52W High
$9.82
52W Low
$3.28
ADV30
92,027
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 5,862,000 | 4,984,000 | -11,399,000 | -13,153,000 | 36,017,000 | 11,198,000 | 31,710,000 |
| Mar 2026 | 5,023,000 | 4,134,000 | -9,715,000 | -9,682,000 | 38,786,000 | 20,600,000 | 22,731,000 |
| Dec 2025 | 5,092,000 | 3,691,000 | -6,946,000 | -8,074,000 | 47,131,000 | 30,147,000 | 22,388,000 |
| Sep 2025 | 14,344,000 | 13,235,000 | 1,627,000 | -274,000 | 40,896,000 | 21,097,000 | 57,936,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,347,000
Investing CF
$8,000
Financing CF
$9,411,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.67
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-347,748,000
Inventory
$2,712,000
Receivables
$11,090,000
ST Investments
—
EBIT TTM
$-27,451,000
Pretax Income TTM
$-31,183,000
Interest Exp TTM
$3,732,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$30,321,000
EBITDA
$-25,964,000
Free Cash Flow
$-9,037,125
Enterprise Value
$74,959,840
Total Cash
$11,198,000
Total Debt
$1,810,000
Shares Out
17,178,786
Trailing EPS
$-1.74
Book Value
$0.25
ROE
—
ROA
-44.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 35,577,000 | -11,939,000 | -17,886,000 | 47,131,000 | 22,388,000 | 24,743,000 | -17,627,000 |
| Dec 2024 | 7,566,000 | -65,836,000 | -76,579,000 | 54,134,000 | 63,994,000 | -9,860,000 | -60,927,000 |
| Dec 2023 | 5,124,000 | -63,222,000 | -66,995,000 | 81,597,000 | 61,834,000 | 19,763,000 | -38,577,000 |
| Dec 2022 | 9,032,000 | -21,296,000 | -24,487,000 | 44,721,000 | 4,688,000 | 40,033,000 | -18,650,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,658,000
NetIncome TTM
$-32,602,000
OpCashFlow TTM
$0
Assets (Latest)
$47,131,000
Forward EPS
$-1.48
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $4.57 · call volume: 1 · put volume: 65
Expected Move to 2026-12-18:
±$1.65
(36.11%) —
implied range
$2.92 –
$6.22
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FBIO | Fortress Biotech, Inc. | $76.04M | $2.28 | — |
| IBIO | iBio, Inc. | $76.53M | $1.19 | — |
| MAIA | MAIA Biotechnology, Inc. | $73.00M | $1.20 | — |
| ALDX | Aldeyra Therapeutics, Inc. | $72.69M | $1.21 | — |
| GANX | Gain Therapeutics, Inc. | $77.69M | $1.78 | — |
News headlines (Yahoo Finance, 1h cache)
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
2026-09-10 12:05 · Yahoo
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
Verrica completes enrolment in Phase III trial of Ycanth
2026-08-28 10:47 · Yahoo
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
2026-08-27 12:00 · Yahoo
Verrica Pharmaceuticals Q2 Earnings Call Highlights
2026-08-07 19:04 · Yahoo
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates
2026-08-06 23:10 · Yahoo
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
2026-08-06 20:01 · Yahoo
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
2026-06-22 12:05 · Yahoo
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
2026-05-28 12:05 · Yahoo
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call
2026-05-13 09:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.